# Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin

> **NCT00039013** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 336 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** AC2993
- **DRUG:** AC2993
- **DRUG:** Placebo
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00039013
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-03
- **Primary completion:** 2003-06
- **Final completion:** 2003-06
- **Target enrollment:** 336 (ACTUAL)
- **Last updated:** 2015-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00039013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00039013, "Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00039013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*